Evidence map›Paper›PMID 34485539›Full record

ReviewBeni-Suef University journal of basic and applied sciences2021

Phage therapy as a revolutionary medicine against Gram-positive bacterial infections.

Archana Loganathan, Prasanth Manohar, Kandasamy Eniyan, C S VinodKumar, Sebastian Leptihn, Ramesh Nachimuthu

Open access · diamondAbstract readReview
In one paragraph

Review in Beni-Suef University journal of basic and applied sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Bacteriophage Therapy AgainstMicroorganisms · 2026
    Review
  5. Phagetherapy updates: New frontiers against antibiotic resistance.European journal of microbiology & immunology · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Pharmaceutics · 2023
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Case report: Successful treatment of recurrentFrontiers in pharmacology · 2023
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Archana LoganathanSchool of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu India.
Prasanth ManoharZhejiang University-University of Edinburgh (ZJU-UoE) Institute, Zhejiang University, School of Medicine, Haining, 314400 Zhejiang People's Republic of China.
Kandasamy EniyanSchool of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu India.
C S VinodKumarDepartment of Microbiology, S.S. Institute of Medical Sciences and Research Centre, Davanagere, India.
Sebastian LeptihnZhejiang University-University of Edinburgh (ZJU-UoE) Institute, Zhejiang University, School of Medicine, Haining, 314400 Zhejiang People's Republic of China.
Ramesh NachimuthuSchool of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu India.
Vellore Institute of Technology University · INZhejiang University-University of Edinburgh Institute · CNShamnur Shivashankarappa Institute of Medical Sciences & Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntibiotic resistance among pathogenic bacteria has created a global emergency, prompting the hunt for an alternative cure. Bacteriophages were discovered over a century ago and have proven to be a successful replacement during antibiotic treatment failure. This review discusses on the scientific investigation of phage therapy for Gram-positive pathogens and general outlook of phage therapy clinical trials and commercialization. MAIN BODY OF THE ABSTRACT: This review aimed to highlight the phage therapy in Gram-positive bacteria and the need for phage therapy in the future. Phage therapy to treat Gram-positive bacterial infections is in use for a very long time. However, limited review on the phage efficacy in Gram-positive bacteria exists. The natural efficiency and potency of bacteriophages against bacterial strains have been advantageous amidst the other non-antibiotic agents. The use of phages to treat oral biofilm, skin infection, and recurrent infections caused by Gram-positive bacteria has emerged as a predominant research area in recent years. In addition, the upsurge in research in the area of phage therapy for spore-forming Gram-positive bacteria has added a wealth of information to phage therapy. SHORT

conclusionWe conclude that the need of phage as an alternative treatment is obvious in future. However, phage therapy can be used as reserve treatment. This review focuses on the potential use of phage therapy in treating Gram-positive bacterial infections, as well as their therapeutic aspects. Furthermore, we discussed the difficulties in commercializing phage drugs and their problems as a breakthrough medicine.

Indexed as

Antibiotic resistanceFuture medicineGram-positive pathogensPhage commercializationPhage productsPhage therapy

Identifiers

PMID34485539
PMCPMC8401357
OpenAlexW3196415182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.